HFSA's 21st Annual Scientific Meeting

"Smart" Therapy in Heart Failure: From Remote Monitoring to Assisted Circulation

Sep 18, 2017 5:30pm ‐ Sep 18, 2017 7:30pm

Expiration Date: Sep 18, 2019


Credits: None available.

Standard: Free

Description

LEARNING OBJECTIVES

Following this activity, participants will be able to:

  • Describe the importance of hemodynamics in the progression of heart failure.
  • Identify remote monitoring and device therapies that can be used to
    evaluate and manage patients with the different stages of heart failure.
  • Correlate interventions in response to PA pressure monitoring which can
    lead to decreased hospitalizations for heart failure.
  • Discuss the options for patients when pharmacotherapy is not effective.
  • Identify current research in progress, which may lead to the next
    generation of monitoring and therapy.
  • Discuss specific case examples in relation to recommended management
    and treatment.
  • Understand the limitations of medical therapy in heart failure.
  • Define practical strategies to evaluate patients for advanced
    technological therapy.
  • Outline the current challenges in Left Ventricular Assist Device (LVAD) therapy.

HFSA PLANNER/REVIEWER DISCLOSURE INFORMATION

  • Karol Harshaw-Ellis, MSN, DNP, GNP, A/ACNP-BC indicated the following relationships: 
    • Speaker-Honoraria for Physicians Education Resource, Novartis 
    • Consultant-Advisory Board for Novartis
  • Kenneth Margulies, MD indicated the following relationships: R
    • Research Grant from Merck, Sharp and Dohme Corporation, Sanofi Pharmaceuticals, Inc., Biosense Webster, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Luitpold Pharmaceuticals, Inc. 
    • Consultant-Advisory Board for Merck, Sharp and Dohme Corporation, GlaxoSmithKline, Janssen Pharmaceuticals, Luitpold Pharmaceuticals, Inc.
  • James Fang, MD indicated the following relationships:
    • Consultant-Advisory Board for Capricor, Actelion, CardioCell
  • Robert Page, PharmD, MSPH, FCCP, FASHP, FASCP, FAHA, BCPS, CGP indicated he has nothing to disclose.
  • Viorel G. Florea, MD, PhD, DSc indicated he has nothing to disclose.
  • Lynne Warner Stevenson, MD indicated the following relationships: 
    • Research Grant from Novartis 
    • Consultant-Advisory Board for Novartis
  • David Whellan, MD indicated he has nothing to disclose.
  • Jaime Abreu, MBA indicated she has nothing to disclose.
  • Shauna Brown, MSL, PCMH CCE indicated she has nothing to disclose.
  • Dawn Saterdalen, RN, MBA indicated she has nothing to disclose.
  • Lexi Saterdalen, AAS, BS indicated she has nothing to disclose.
  • Denise Broderick, BSc indicated she has nothing to disclose.

Speaker(s):

Disclosures

  • William Abraham, MD:

    William Abraham, MD, FACP, FACC, FAHA, FESC indicated he has nothing to disclose.

  • Mandeep Mehra, MD:

    Mandeep Mehra, MD, FACC, FESC, FRCP indicated the following relationships:

    • Consultant-Advisory Board for Abbott, Johnson & Johnson, Medtronic, Teva, Stealth
      Biotherapeutics, Portola Pharmaceuticals
  • Akshay Desai, MD, MPH:

    Akshay Desai, MD indicated the following relationships:

    • Research Grant from Novartis
    • Consultant-Advisory Board for Novartis, St. Jude/Abbott Medical, AstraZeneca,
      Janssen, Relypsa, DalCor, Cheetah Medical
  • Sitaramesh Emani, MD:

    Sitaramesh Emani, MD indicated the following relationships:

    • Research Grant from Abbott
    • Speaker-Honoraria for Abbott
    • Consultant-Advisory Board for Abbott, Medtronic, Boston Scientific, CHF Solutions, CareDx

  • Anuradha Lala-Trindade, MD:

    Anuradha Lala-Trindade, MD indicated she has nothing to disclose.

  • Keith Aaronson, MD:

    Keith Aaronson, MD, MS indicated he has nothing to disclose.

Credits Available


2017 "Smart" Therapy: Credit Information

You must be logged in and own this session in order to post comments.

Julie Chesson
5/20/18 1:53 pm

Amber Hevel
6/21/18 3:41 am

great

Jade Carrere
7/26/18 2:18 pm

Such great information!

paolo Legaspi
8/16/18 1:44 am

good